Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

The pivotal Phase 3 trial for Cylembio® in advanced melanoma showed clinical improvement in progression free survival, but missed its primary endpoint for statistical significance (p=0.056; threshold ...

TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel ...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

Pyxis Oncology anticipates having preliminary data from the Phase 1/2 combination study of MICVO in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in R/M HNSCC and other ...

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...

The trial tests BNT113, a biological treatment administered via IV injection, in combination with pembrolizumab, an IV infusion, to enhance therapeutic outcomes for patients with specific head and ...

AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase III clinical study titled A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator’s Choice of ...